(R)-3-(3-hydroxypyrrolidin-1-yl)propionitrile | 680223-89-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-3-(3-hydroxypyrrolidin-1-yl)propionitrile
• 英文别名: 3-(3-hydroxypyrrolidin-1-yl)propionitrile；3-(3-Hydroxypyrrolidin-1-yl)propanenitrile
• CAS: 680223-89-6
• 化学式: C₇H₁₂N₂O
• 分子量: 140.185
• InChiKey: WVOXJBSAWSCZLL-UHFFFAOYSA-N

物化性质

• 沸点：
  310.3±32.0 °C(Predicted)
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  47.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  右美托咪定杂质6 、 (R)-3-(3-hydroxypyrrolidin-1-yl)propionitrile 以3-[2-(3-hydroxypyrrolidin-1-yl)ethyl]-5-methyl-2H-isoquinolin-1-one (157.5 mg) was obtained的产率得到3-[2-(3-hydroxypyrrolidine-1-yl)ethyl]-5-methyl-2H-isoquinoline-1-one
  参考文献：
  名称：

  Isoquinoline compound and pharmaceutical use thereof

  摘要：

  本发明涉及一种由以下式（I）表示的异喹啉化合物，其光学活性形式，其药学上可接受的盐，其水加合物，其水合物和其溶剂合物，以及用于预防和/或治疗由多聚（ADP-核糖）聚合酶的高反应性引起的疾病的药物，其中包含该化合物，以及含有该化合物的多聚（ADP-核糖）聚合酶抑制剂。此外，该化合物可用作预防和/或治疗脑梗死的药物，特别是作为预防和/或治疗急性脑梗死的药物。此外，该化合物可用作预防和/或治疗与脑梗死相关的神经症状的预防和/或治疗剂，特别是急性脑梗死。其中符号与说明中定义的相同。

  公开号：

  US20040248931A1

文献信息

• ISOQUINOLINE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Fujio Masakazu

  公开号：US20070161620A1

  公开（公告）日：2007-07-12

  The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction. wherein the symbols are the same as defined in the description.

  本发明涉及以下式(I)所表示的异喹啉化合物，其手性活性形式，其药学上可接受的盐，其水加合物，其水合物和其溶剂化物，以及包含该化合物的用于预防和/或治疗由多聚(ADP-核糖)聚合酶过度反应所致疾病的药剂和包含该化合物的多聚(ADP-核糖)聚合酶抑制剂。此外，该化合物可用作预防和/或治疗脑梗死的药剂，特别是作为预防和/或治疗急性脑梗死的药剂。此外，该化合物可用作改善与脑梗死相关的神经症状的预防性和/或治疗性药剂，特别是急性脑梗死。其中符号与描述中定义的相同。
• INHIBITORS OF HUMAN TUMOR-EXPRESSED CCXCKR2
  申请人：Melikian Anita

  公开号：US20100144720A1

  公开（公告）日：2010-06-10

  Pharmaceutical compositions containing organic compounds or salts thereof that serve as modulators for the SDF-1 or I-TAC chemokines are disclosed. The compounds and compositions are useful in the treatment of cancer, especially in the inhibition of cancer proliferation, growth, and metastasis. Methods of interfering with SDF-1 and/or I-TAC binding to the CCXCKR2 receptor and treating cancer using the compounds and pharmaceutical compositions of the present invention are also disclosed.

  本发明涉及含有有机化合物或其盐的制药组合物，其作为SDF-1或I-TAC趋化因子的调节剂。这些化合物和组合物在癌症治疗中特别是在抑制癌症增殖、生长和转移方面具有用途。本发明还揭示了干扰SDF-1和/或I-TAC与CCXCKR2受体结合以及使用本发明的化合物和制药组合物治疗癌症的方法。
• ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1557414A1

  公开（公告）日：2005-07-27

  The present invention relates to an isoquinoline compound represented by the following formula (1), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct thereof, a hydrate thereof and a solvate thereof, as well as an agent for the prophylaxis and/or treatment of a disease caused by hyperreactivity of poly(ADP-ribose)polymerase, containing the compound, and a poly(ADP-ribose)polymerase inhibitor containing the compound. In addition, this compound is useful as an agent for the prophylaxis and/or treatment of cerebral infarction, particularly as an agent for the prophylaxis and/or treatment of acute cerebral infarction. Furthermore, this compound is useful as a prophylactic and/or therapeutic agent that improves neurological symptoms associated with cerebral infarction, particularly acute cerebral infarction.

  本发明涉及下式(1)代表的异喹啉化合物、其光学活性形式、其药学上可接受的盐、其水加合物、其水合物和其溶解物，以及含有该化合物的预防和/或治疗由聚(ADP-核糖)聚合酶高反应性引起的疾病的制剂和含有该化合物的聚(ADP-核糖)聚合酶抑制剂。此外，该化合物还可作为预防和/或治疗脑梗塞的药物，特别是作为预防和/或治疗急性脑梗塞的药物。此外，该化合物还可作为预防和/或治疗剂，改善与脑梗塞，尤其是急性脑梗塞相关的神经症状。
• INHIBITORS OF THE BINDING OF CHEMOKINES I-TAC OR SDF-1 TO THE CCXCKR2 RECEPTOR
  申请人：ChemoCentryx, Inc.

  公开号：EP1606251B1

  公开（公告）日：2009-04-08
• US7220759B2
  申请人：——

  公开号：US7220759B2

  公开（公告）日：2007-05-22